Condition: Non-Hodgkin Lymphoma, Adult · Non-Hodgkin Lymphoma, Refractory · Non-Hodgkin Lymphoma, Relapsed · Sponsor: Marker Therapeutics, Inc.
This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing).
This description comes directly from the study's public registry record.
Juan Vera, MD · 1 (713) 591-8100 · jvera@markertherapeutics.com
Patricia Allison · 1 (717) 471-5205 · pallison@markertherapeutics.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| University of Colorado | Aurora, Colorado, United States | Recruiting |
| Colorado Blood Cancer Institute (Sarah Cannon) | Denver, Colorado, United States | Recruiting |
| University of Kansas Medical Center | Kansas City, Kansas, United States | Recruiting |
| Cornell | New York, New York, United States | Recruiting |
| Sarah Cannon Research Institute at St. David's South Austin | Austin, Texas, United States | Recruiting |
| University of Wisconsin Carbone Cancer Center | Madison, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05798897